Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$0.16
-3.1%
$0.26
$0.14
$3.87
$38.77M215.08 million shs38.29 million shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$10.22
+8.0%
$8.86
$3.65
$10.99
$214.39M0.83347,568 shs3.22 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.53
+1.3%
$1.30
$0.98
$1.61
$1.14B1.52.69 million shs8.41 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-3.15%-4.76%-26.57%-53.82%-88.24%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
+7.98%+13.25%+13.75%+86.41%+127.51%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+1.32%+7.75%+17.69%+36.61%+20.47%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$0.16
-3.1%
$0.26
$0.14
$3.87
$38.77M215.08 million shs38.29 million shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$10.22
+8.0%
$8.86
$3.65
$10.99
$214.39M0.83347,568 shs3.22 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.53
+1.3%
$1.30
$0.98
$1.61
$1.14B1.52.69 million shs8.41 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-3.15%-4.76%-26.57%-53.82%-88.24%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
+7.98%+13.25%+13.75%+86.41%+127.51%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+1.32%+7.75%+17.69%+36.61%+20.47%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
2.20
Hold$4.502,712.50% Upside
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
2.86
Moderate Buy$17.1768.05% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.17
Hold$1.551.31% Upside

Current Analyst Ratings Breakdown

Latest KPTI, GOSS, and OPK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2026
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Lower Price TargetBuy$5.00 ➝ $2.00
6/18/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Reiterated RatingBuy
6/9/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Reiterated RatingOverweight
5/26/2026
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Reiterated RatingBuy$5.00
5/19/2026
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
DowngradeSell (D-)Sell (E+)
5/18/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
UpgradeSell (E+)Sell (D-)
5/6/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Boost Price TargetBuy$8.00 ➝ $13.00
5/4/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeSell (D-)Sell (E+)
4/29/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeOutperformMarket Perform
4/27/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Reiterated RatingOverweight$8.00 ➝ $16.00
4/21/2026
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Reiterated RatingSell (D-)
(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$55.54M0.68N/AN/A($0.53) per share-0.30
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$146.07M1.58N/AN/A($16.00) per share-0.64
OPKO Health, Inc. stock logo
OPK
OPKO Health
$606.90M1.90N/AN/A$1.67 per share0.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$170.37M-$0.79N/AN/AN/A-324.82%N/A-96.10%8/4/2026 (Estimated)
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$196.04M-$15.09N/AN/AN/A-129.02%N/A-120.29%8/10/2026 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-36.63%-16.78%-10.98%7/30/2026 (Estimated)

Latest KPTI, GOSS, and OPK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2026Q1 2026
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.17-$0.20-$0.03-$0.20$4.67 million$16.96 million
5/14/2026Q1 2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$1.45-$1.24+$0.21-$1.24$31.40 million$35.07 million
4/28/2026Q1 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.07N/A-$0.07$130.51 million$124.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
N/AN/AN/AN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
N/A
2.20
2.20
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/A
1.08
1.05
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17

Institutional Ownership

CompanyInstitutional Ownership
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
81.23%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
66.44%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.74%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
1.68%
OPKO Health, Inc. stock logo
OPK
OPKO Health
44.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
180234.70 million225.92 millionOptionable
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
38022.66 million22.28 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million417.42 millionOptionable

Recent News About These Companies

Spotlight On Promising Penny Stocks For May 2026

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gossamer Bio stock logo

Gossamer Bio NASDAQ:GOSS

$0.16 -0.01 (-3.15%)
Closing price 06/26/2026 03:59 PM Eastern
Extended Trading
$0.16 +0.00 (+1.25%)
As of 06/26/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Karyopharm Therapeutics stock logo

Karyopharm Therapeutics NASDAQ:KPTI

$10.22 +0.76 (+7.98%)
Closing price 06/26/2026 03:59 PM Eastern
Extended Trading
$10.15 -0.06 (-0.64%)
As of 06/26/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.53 +0.02 (+1.32%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$1.55 +0.02 (+1.31%)
As of 06/26/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.